Normalising Renin After Medical Therapy for Primary Aldosteronism May Lower Cardiovascular Risk — But RCTs Are Needed
Posted inCardiology Diabetes & Endocrinology news

Normalising Renin After Medical Therapy for Primary Aldosteronism May Lower Cardiovascular Risk — But RCTs Are Needed

A 2025 systematic review and meta-analysis found that patients with primary aldosteronism whose renin rose after mineralocorticoid receptor antagonist therapy had substantially lower cardiovascular event rates and possibly lower mortality, suggesting renin normalisation as a therapeutic target pending prospective confirmation.
Cyclic Cushing’s Syndrome: International Cohort Reveals Diagnostic Pitfalls, High Complication Rates, and Practical Strategies for Clinicians
Posted inDiabetes & Endocrinology news

Cyclic Cushing’s Syndrome: International Cohort Reveals Diagnostic Pitfalls, High Complication Rates, and Practical Strategies for Clinicians

An international retrospective cohort of 110 patients with cyclic Cushing’s syndrome highlights frequent diagnostic delays, imaging misses, inappropriate surgeries, high rates of spontaneous adrenal insufficiency, and variable outcomes — prompting practical recommendations for testing, sampling timing, and peri‑care planning.
Tailored Implementation of Systems Navigation and Psychosocial Counselling to Enhance HIV Care Engagement among People Who Inject Drugs in Viet Nam: Evidence from a Cluster-Randomised Trial
Posted inClinical Updates HIV/AIDS news

Tailored Implementation of Systems Navigation and Psychosocial Counselling to Enhance HIV Care Engagement among People Who Inject Drugs in Viet Nam: Evidence from a Cluster-Randomised Trial

A tailored approach to implementing systems navigation and psychosocial counselling significantly improved intervention fidelity and viral suppression among people with HIV who inject drugs in Viet Nam, compared to a standard strategy, highlighting the value of context-sensitive interventions.
Mirikizumab Shows Promising Efficacy and Acceptable Safety in Pediatric Moderately-to-Severely Active Ulcerative Colitis: Results from the SHINE-1 Phase 2 Trial
Posted inGastroenterology news Pediatrics

Mirikizumab Shows Promising Efficacy and Acceptable Safety in Pediatric Moderately-to-Severely Active Ulcerative Colitis: Results from the SHINE-1 Phase 2 Trial

The multicentre open-label SHINE-1 phase 2 trial found that mirikizumab produced clinically meaningful induction and maintenance responses in children with moderate-to-severe ulcerative colitis, with an acceptable safety profile over 52 weeks, supporting further randomized evaluation.
Camrelizumab plus Rivoceranib Delivers Substantial Survival Gain over Sorafenib in First‑line Unresectable HCC: Final CARES‑310 Results
Posted innews Oncology

Camrelizumab plus Rivoceranib Delivers Substantial Survival Gain over Sorafenib in First‑line Unresectable HCC: Final CARES‑310 Results

Final CARES-310 analysis shows camrelizumab plus rivoceranib significantly improves overall survival versus sorafenib in first-line unresectable hepatocellular carcinoma, with increased but manageable toxicity. Results support the combination as an additional frontline option, especially where other immunotherapy regimens are unavailable.
Total Neoadjuvant Therapy Enables Organ Preservation Without Compromising Distant Control in pMMR/MSS Stage II–III Rectal Cancer: Insights from the NO-CUT Trial
Posted inGastroenterology news Oncology

Total Neoadjuvant Therapy Enables Organ Preservation Without Compromising Distant Control in pMMR/MSS Stage II–III Rectal Cancer: Insights from the NO-CUT Trial

The NO-CUT phase 2 trial shows that total neoadjuvant therapy (CAPOX-based TNT) followed by non-operative management for clinical complete responders achieved high 30‑month distant relapse‑free survival (95%) and enabled organ preservation in 26% of patients with pMMR/MSS stage II–III rectal cancer.
A Standardized RANO Resection Classification Links Supramaximal Surgery to Meaningful Survival Gains in IDH‑Mutant Grade 2 Glioma
Posted inNeurology news Oncology

A Standardized RANO Resection Classification Links Supramaximal Surgery to Meaningful Survival Gains in IDH‑Mutant Grade 2 Glioma

An international retrospective cohort (n=1,391) validates a four‑tier RANO classification of residual T2‑FLAIR volume: supramaximal resection confers the largest survival benefit, with graded, durable advantages for maximal versus submaximal resections across IDH‑mutant astrocytoma and oligodendroglioma.
Microbubble‑Enhanced Focused Ultrasound with Temozolomide Shows Feasibility and Promising Survival in High‑Grade Glioma — Phase 1/2 Multicentre Results
Posted inNeurology news Oncology

Microbubble‑Enhanced Focused Ultrasound with Temozolomide Shows Feasibility and Promising Survival in High‑Grade Glioma — Phase 1/2 Multicentre Results

A multicentre phase 1/2 trial reports that MRI‑guided microbubble‑enhanced transcranial focused ultrasound (MB‑FUS) can safely open the blood–brain barrier and be combined with standard adjuvant temozolomide in high‑grade glioma, with median overall survival 31.3 months and feasibility for non‑invasive plasma biomarker monitoring.
High Viral Suppression with TLD in PEPFAR Programs — But Resistance and Adherence Signals Require Targeted Action
Posted inHIV/AIDS Infectious Diseases news

High Viral Suppression with TLD in PEPFAR Programs — But Resistance and Adherence Signals Require Targeted Action

A multinational prospective cohort found high viral suppression after switching or initiating tenofovir–lamivudine–dolutegravir (TLD), but emergent dolutegravir-resistance was detected in a small subgroup with prior virological failure and poor adherence, highlighting the need for monitoring and adherence support.
Surgical aortic valve replacement produces about twice the carbon footprint of transcatheter approaches: clinical and stewardship implications
Posted inCardiology news Public Health

Surgical aortic valve replacement produces about twice the carbon footprint of transcatheter approaches: clinical and stewardship implications

A life cycle assessment found SAVR emits ~620–750 kg CO2e per case—roughly double OR- or cath-lab TAVR (~280–360 kg CO2e). ICU length of stay and postoperative care were the dominant contributors, highlighting targets for low-carbon perioperative pathways and policy-level decision-making.
SMARCA4-altered Resectable and Advanced NSCLC: Neoadjuvant Immunochemotherapy Works for Squamous, But KRAS+STK11/KEAP1 Co-mutations Define an Immune‑Cold High‑Risk Subset
Posted innews Oncology Respiratory

SMARCA4-altered Resectable and Advanced NSCLC: Neoadjuvant Immunochemotherapy Works for Squamous, But KRAS+STK11/KEAP1 Co-mutations Define an Immune‑Cold High‑Risk Subset

Two contemporary series show that SMARCA4‑altered NSCLC is molecularly and clinically heterogeneous: squamous tumors have high pathologic responses to neoadjuvant immunochemotherapy, while non‑squamous tumors—especially those with co‑occurring KRAS and STK11/KEAP1 alterations—are immune‑cold and have poor outcomes despite chemoimmunotherapy.
Dual Pathology No Longer a Dead End: Tafamidis and AVR Improve Survival in Aortic Stenosis with Cardiac Transthyretin Amyloidosis
Posted inCardiology news

Dual Pathology No Longer a Dead End: Tafamidis and AVR Improve Survival in Aortic Stenosis with Cardiac Transthyretin Amyloidosis

In a multinational registry of patients with concomitant aortic stenosis (AS) and transthyretin cardiac amyloidosis (ATTR‑CA), both ATTR‑specific therapy (predominantly tafamidis) and aortic valve replacement (AVR) were independently associated with lower mortality. Combined therapy produced outcomes comparable to lone AS treated with AVR.